Status:
NO_LONGER_AVAILABLE
Individual Patient Compassionate Use of GX-I7
Lead Sponsor:
Genexine, Inc.
Conditions:
Glioblastoma
High Grade Glioma
Brief Summary
Compassionate use of GX-I7 for patients with serious life-threatening illness that have exhausted all available therapies, with no other therapy options.
Detailed Description
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.
Eligibility Criteria
Inclusion
- \-
Exclusion
- \-
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04289155
Last Update
March 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kangnam St. Mary's Hospital
Seoul, South Korea, 137-701